Literature DB >> 9565972

[Thyroid gland function in lithium treatment].

T Bschor1, M Bauer.   

Abstract

Lithium is widely used in the acute and prophylactic treatment of affective disorders. Lithium affects thyroid hormone metabolism via different mechanisms. In patients this leads to a compensatory increase in pituitary thyroid stimulating hormone (TSH) which usually maintains the euthyroid status. This is probably the reason for the relatively high prevalence of goitre in lithium-treated patients; however, the enlargement of the gland is only moderate in most cases. Due to its immunostimulating effects lithium may support the appearance of thyroid auto-antibodies and the development of thyroiditis, which may be the reason for a higher prevalence of hypothyroidism in patients receiving lithium. However, also cases of hyperthyroidism in such patients have been reported repeatedly. Therapeutic recommendations for the treatment of disturbances of thyroid function during lithium treatment are given.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565972     DOI: 10.1007/s001150050259

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  4 in total

1.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

2.  Lithium therapy: an unusual cause of elevated and diffuse radioactive iodine uptake.

Authors:  Ebenezer A Nyenwe; Joseph N Fisher; Lester Vanmiddlesworth
Journal:  J Radiol Case Rep       Date:  2008-10-01

Review 3.  [Side effects and risk profile of lithium: critical assessment of a systematic review and meta-analysis].

Authors:  T Bschor; M Bauer
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

Review 4.  Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.